Real-world study evaluates second-line treatment efficacy following first-line immunotherapy in advanced NSCLC, suggesting treatment options for better outcomes.
Immune checkpoint inhibitors (ICIs) are standard first-line therapy for driver-negative advanced non-small cell lung cancer (NSCLC) but face early resistance. The optimal second-line strategy after progression remains undefined. This dual-center study evaluated the efficacy of various second-line treatments in this real-world patient population.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: